Introduction to Musculoskeletal Tumor Center, Peking University People's Hospital

(M.S.T.C., PKUPH)

This year is the 20^th anniversary of the founding of the Musculoskeletal Tumor Center at Peking University People's Hospital.Prof. Wanpeng Xu firstly came to PKUPH as the chief of orthopedic oncologyfrom Jishuitan Hospital and founded this department in 1997. Prof. Wei Guo was then assigned as the chief as Prof. Xu resigned in 2002 and the division was officially named as the Musculoskeletal Tumor Center in 2003.With efforts of several generations,the center has been awarded as the National Key Institute for Sarcoma Treatment and recognized as a renowned sarcoma center around the world. Besides, our center has gained tremendous achievement in basic research. Prof. Chuanhan Feng first performed pioneering study on the giant cell tumor in the Chinese population and gained worldwide recognition for his dedicated work.The research achievement won the first prize of Beijing Scientific and Technological Progress in 1980 and the second prize of National Board of Education Scientific and Technological Progress in 1999. And our laboratory was rated as Key Laboratory of Beijing for Sarcoma Research in 2013.

1)       Overview & Staffs

The M.S.T.C., PKUPH is the Key Discipline for National Ministry of Education and Health, which includes two inpatient wards and one laboratory. We have 99 open beds for patients and 25 physicians in this center, of whom there are 6 professors, 7 associate professors, 7 consultants, 4 residents. There are also 38 nurses, 1 associate researcher as well as 2 lab technicians in our group.

For physicians, during the founding period of this center, there wereProf. Wanpeng Xu, Baoguo Jiang, Wei Guo, Rongli Yang, Xiafei Ren, Rui Yang, Xiaodong Tang, Nan Li.Postgraduates were Maoting Li and Yi Guo. Xiafei Ren left for Singapore in 1999, Rui Yang left for the U.S.A. in 2000, Yi Guo left for the U.S.A. in 2003 and Nan Li left for the U.S.A. in 2005. In 1999 Baoguo Jiang left this department to Orthopaedic trauma. At the end of 1999, Taiqiang Yan joined in this department. Shun Tang and Huayi Qu joined this group in 1999, Dasen Li and Yi Yang joined in 2000, Sen Dong joined us in 2001, Xiao Li joined in 2002, Tao Ji joined in 2004, Xin Sun joined in 2005, Jie Zang and Zhiye Du joined in 2007, Lu Xie and Yidan Zhang joined this group in 2011, Yifei Wang joined in 2012, Ran Wei joined in 2013, Jie Xu joined in 2014, Jichuan Wang and Ruifeng Wang joined in 2015, Jun Wang joined in 2016, Haijie Liang and Shidong Wang joined us in 2017. As for nursing supervisor, the first one was Xiangyan Kong but then she was moved to Orthopaedic trauma in 1999. Peichun Cao came to our department from Orthopaedic Joint in 1999 and she has been our nurse manager since then.

2)       Features of medical services

Since the foundation of this center, we have treated more than 17,000 patients, of whom more than 16,000 are for surgeries.

For the last five years, we have admitted an average of 2,000 in-patients and done an average of 1,700 surgeries per year. The main features of medical services include: 1) Limb salvage therapy for malignant bone and soft tissue sarcomas:The limb salvage surgery has always been the key point for the surgery for malignant bone tumors. The limb sparing rate should also be considered as an important index to evaluate the therapeutic level of an orthopedic oncology department. We have investigated various limb salvage procedures, which included prosthetic replacement for joint, limb sparing surgeries for pediatric patients, allogeneic inactivated bonegraft, autologous bone graft and so on. 2) Resection and reconstruction of pelvic malignant tumors:The resection and reconstruction of pelvic malignant tumors have been considered as the strengths of our department, especially for the resection of peri-acetabular malignant tumors and reconstruction with prosthesis, which were deemed to be at the leading position in domestic andabroad. We usually complete an average of 220 pelvic surgeries per year and the mortality is controlled as low as 0.5%. 3) Resection of sacral malignant tumors:It is considered to be highly difficult and risky to resect sacral tumors. And the resection and reconstruction of sacral tumors in our department should be deemed to be at the highest level in China. We complete an average of 230 surgeries for sacral tumors per year, most of which are also supposed tobe extremely complicated internationally. Above all, the total sacrectomy through single posterior approach should be representative of the highest surgical leveland we are nowadays trying hard to reduce the peri-operative mortality and complications.4) Surgical therapy for spinal tumors:Spinal tumors, especially spinal metastatic tumors have gradually increased in recent years. We were the first to carry out one-stage total spondylectomywith posterior approach at 2007 in China and approximately 260 spinal surgeries are done every year.

Table 1: the list of technological innovation of surgery

Time (year)	Innovation project	Type
2007	One-stage total spondylectomy with posterior approachfor spinal tumors	Spine & sacrum
2007	The surgical partitions and approaches for sacral tumors	Spine & sacrum
2007	The en bloc resection of sacral tumors	Spine & sacrum
2009	The surgical classifications and resection for sacral neurogenic tumors	Spine & sacrum
2009	One-stage total sacrectomy with anterior and posterior combined approaches	Spine & sacrum
2012	Total sacrectomy by posterior approach only	Spine & sacrum
2011	En bloc resection of tumor involving partial sacrum and ipsilateral sacroiliac joint with reservationof contralateral sacral foramina	Spine & sacrum
2015	The design and application of sacral prosthesis with 3D Printing method	Spine & sacrum
2016	The separation surgery for sacral tumors	Spine & sacrum
2016	The research and development of compoundvertebraeprosthesis with 3D Printing method	Spine
2016	The research and development of extensible vertebrae prosthesis	Spine
2003	Using hypertonic saline-induced devitalized autologous bone graft for bony reconstruction in musculoskeletal tumor surgery	Limb salvage
1997	The design and application of pediatric hemi-articularprosthesis for tumor resection	Pediatric limb salvage
2007	Pediatric half-restrictive distal femoral prosthesis with reservation of proximal tibial epiphysis	Pediatric limb salvage
2006	The clinical application of Stryker compound joint prosthesis	Limb salvage
2010	The design and application of domestic compound joint prosthesis	Limb salvage
2011	The application of Link compoundbiological-fixed joint prosthesis	Limb salvage
2011	Bone extension technologyfor pediatric discrepancy of lower extremities after cure of osteosarcoma	Limb salvage
2017	Extendible joint prosthesis for pediatric malignant bone tumors	Limb salvage
2017	Artificial joint prosthesis with extendible handle for pediatric discrepancy of lower extremities after cure of osteosarcoma	Limb salvage
2017	Restrictive artificial semi-joint prosthesis for malignant bone tumors	Limb salvage
2016	Replantation of inactivated tumor bone combined with vascularized fibular graft	Pediatric limb salvage
2004	The resection of tumors located at alae sacralis and reconstruction with screw-rod fixation system	Pelvis
2003	The design and clinical use of adjustable semi-pelvic prosthesis	Pelvis
2008	Surgical resection and reconstruction of pelvic tumors involving sacrum	Pelvis
2008	The research and development of semi-pelvic prosthesiswith screw-rod fixation system	Pelvis
2012	The development of second-generation of semi-pelvic prosthesis with screw-rod fixation system	Pelvis
2015	The design and clinical use of 3D-printing compound semi-pelvic prosthesis	Pelvis
2015	The design and clinical use of 3D-printing iliac prosthesis	Pelvis
2005	Low-level aortic balloon occlusion technology to decrease blood loss during pelvicsacral tumor resection	Adjuvant therapy
2014	The use of Denosumab to treat refractory sacral and pelvic giant cell tumors	Adjuvant therapy

 

Table 2: the list of the tasks of systemic therapyfor sarcomas

Time (year)	Title
2000-2013	Effects of Arsenic Trioxide Combined with First-line Chemotherapy on Osteosarcoma with Pulmonary Metastasis
2001	The effects of Paclitaxel on advanced osteosarcoma
2013-2014	Clinical observation of preoperative arterial perfusion of cisplatin for osteosarcoma of extremities and efficiency analysis
2010-2016	Retrospective analysis of the efficiency of GT protocol (gemcitabine and docetaxel) as the second-line chemotherapy for osteosarcoma
2013-now	The clinical evaluation of PET/CT for preoperative chemotherapy of osteosarcoma
2014-now	The clinical evaluation of color-doppler ultrasound for adjuvant chemotherapy of bone and soft tissue sarcoma
2016-now	Clinical evaluation of primary sarcoma originated from bone
2014	Mesenchymal Chondrosarcoma of Bone andSoft Tissue: A Systematic Review of 107Patients in the Past 20 Years
2015-now	The use of VIT protocol (vincristine, irinotecan and temozolomide) as the second-line chemotherapy for metastatic Ewing sarcoma
2016-2017	Surgerydefinitive radiotherapy----which option ensures the better clinical outcome and quality of life in pelvicsacral Ewing’s sarcomas?
2016-2018	Prospective trial: A Phase II Trial of Apatinib in Relapsed and Unresectable High-grade Osteosarcoma After Failure of Standard Multimodal Therapy, ClinicalTrials.gov Identifier:NCT02711007
2015	Molecular detection for target therapy of advancedsarcomas
2015-2016	The expression of VEGFR-2 for osteosarcoma patients and its impact on survival
2012-2015	Impact of Genetic Polymorphisms of MTHFR in Osteosarcoma treated with high-dose Methotrexate
2017-2019	Prospective trial: Apatinib for Advanced Soft Tissue Sarcoma Patients After Failure of Traditional Therapy: an One-armed, Phase 2, Open-label, MulticenterTrial, ClinicalTrials.gov Identifier:NCT03104335
2017	Retrospective analysis of the 20 years’ survival of metastatic osteosarcoma from a single institution
2016-now	Balloon catheter hypoxic pelvic perfusion with high dose chemotherapy in the treatment of sarcoma of the pelvic ring
Tasks on-going
2017	The impact of inflammatory factors on prognosis of osteosarcoma patients
2017	Safety and efficacy of combination of PARP inhibitors, temozolomide and irinotecan in patients with advanced Ewing sarcomas
2017	Comparing the safety and efficacy ofpegylated liposomal doxorubicin andpirarnbicin in patients with advancedsoft tissue sarcoma: a randomised, placebo-controlled, phase 2 trial
2017	The detection of Nano-5hmC-Seal as an epigenetic biomarker in osteosarcoma treatment

 

3)       Research funds &Awards

The predecessor of our laboratory was the laboratory founded by Prof. Feng  Chuanhan at 1983, which was the first lab for sarcoma research at PKUPH. We have successfully applied 16 National Science Funds, 7 Beijing science and Technology Funds (3 priority funds included), 2 Ministry of Health Funds, 1 major Basic Research Fund of Ministry of Science and Technology and 5 Doctoral Scientific Funds of the Ministry of Education, since the foundation of this lab. The total amount of funds is approximate 1400 millions (CNY).

We have published more than 300 papers, of which there are more than 80 SCIs (Science Citation Index). And we won 6 National patents of invention and have edited 16 monographs and textbooks.

Table 3: the list of awards

AwardsName	Grade	Year	Details
National Award for Scientific and Technological Progress	Second	2014	Series of research on standardize resection and reconstruction of primary bone sarcomas
ChineseMedical Scientific and Technological Progress award	First	2013	Series of research on standardize resection and reconstruction of primary bone sarcomas
Wu Jie-ping&Yang sen MedicalPrize		2012	Resection of pelvic ring tumors and functional reconstruction
Beijing Scientific and Technological ProgressAward	Second	2011	Resection of pelvic ring tumors and functional reconstruction
ChineseMedical Scientific and Technological ProgressAward	Third	2009	Resection of pelvic ring tumors and functional reconstruction
Beijing Scientific and Technological ProgressAward	Third	2005	Serialbasic and clinical research on chemotherapy for osteosarcoma
ChineseMedical Scientific and Technological ProgressAward	Second	2003	Series of study on the pathogenesis of primary malignant bone tumors
Beijing Scientific and Technological ProgressAward	Third	2003	Series of Research on etiology of primary malignant bone tumors
Beijing Scientific and Technological ProgressAward	Third	2001	Serial molecular biology study on primary malignant bone tumors
National Education Commission Scientific and Technological ProgressAward	Second	1999	The serial research on cytobiology, cytogenetics and immunology of Bone Giant Cell Tumors

 

4)       Publication of Books

1.       The diagnosis and treatment of bone and soft tissue sarcoma. Chief interpreter, 2006, Tianjin science and technology translation and publishing company.

2.       Surgery for pelvic tumors. Editor in chief, 2009, Peking University Press.

3.       Musculoskeletal Oncology. Vice editor in chief, 2008, People’s Medical Publishing House.

4.       Knee Surgery. Vice editor in chief, 2011, People's Medical Publishing House.

5.       Chinese osteology (the branches of orthopedic oncology). Editor in chief, 2010, People's Medical Publishing House.

6.       Spinal oncology. Chief interpreter, 2010, Peking University Press.

7.       Atlas of Orthopedic pathology. Chief interpreter, 2011,Peking University Press.

8.       The surgery of tumor-type artificial joint replacement. Editor in chief, 2011, People's military medical Publisher.

9.       The textbooks of surgery for eight-year medical education system (the chapter of bone tumors). Second edition. 2010, People's Medical Publishing House.

10.   Surgery of bone metastatic tumors. Editor in chief, 2012, People's Medical Publishing House.

11.   Surgery for pelvic tumors. Second edition. Editor in chief, 2015, Peking University Press.

12.   The textbooks of surgery for eight-year medical education system (the chapter of bone tumors). Third edition. 2015, People's Medical Publishing House.

13.   Osteology (the textbook for postgraduates). Vice editor in chief, for the chapter of bone tumors. 2015, People's Medical Publishing House.

14.   Orthopedic surgery (the fourth edition). Editor in chief for the chapter of bone and soft tissue sarcoma. 2015, People's Medical Publishing House.

15.   Modern orthopedic basic and clinic issues. (Second edition). Editor in chief for the chapter of bone tumors. 2014, People's Medical Publishing House.

16.   Surgery (the chapter of bone tumors), digital teaching material of general higher education clinical medicine. 2016, People's Medical Publishing House.

5)       Physicians’cultivation

Name	Country	Medical institution	Time interval for training
Wei Guo	U.S.A.	Memorial sloan-kettering cancer center in New York	2 years
Xiaodong Tang	Australia	Adelaide medical school	1 year
Taiqiang Yan	Canada	Mount sinai hospital, university of Toronto	3 years
Shun Tang	Italy	Rizzolimedical center, Bologna	3 months
Dasen Li	U.S.A.	Memorial sloan-kettering cancer center in New York	2 years
Huayi Qu	U.S.A.	Albert Einstein college of medicine, New York	2 years
Yi Yang	U.S.A.	Albert Einstein college of medicine, New York	2 years
Tingting Ren	U.S.A.	Albert Einstein college of medicine, New York	2 years
Tao Ji	U.S.A.	University of California, Irvine	2 years
Jie Zang	U.S.A.	Mayo Clinic Medical Center	1 year
Xin Sun	Italy	Rizzolimedical center, Bologna	3 months
Xin Sun	U.S.A.	Massachusetts General Hospital, Boston	1 year
Yidan Zhang	U.S.A.	Albert Einstein college of medicine, New York	2 years
Lu Xie	U.S.A.	Mayo Clinic	3 months
Jie Xu	U.S.A.	Mayo Clinic	1 year
Yifei Wang	U.S.A.	M.D. Anderson Cancer Center	2 years

 

6)       Publications

1、郭卫, 冯传汉，等。A Flow Cytometric Study on Giant Cell Tumor of Bone. Chinese Medical Journal (English Ed) 109(2):134,1996

2、郭卫, 冯传汉，等。P53 gene Abnormalities in Osteosarcoma.Chinese Medical Journal. (English Ed) 109(10):752,1996

3、郭卫, 冯传汉，等。骨巨细胞瘤中p53基因的异常。北京医科大学学报27(6):403-405, 1995

4、郭卫, 冯传汉，等。骨巨细胞瘤和骨肉瘤的DNA倍体与增殖活力的研究。北京医科大学学报26(1):7-9, 1994

5、郭卫, 冯传汉，等。骨巨细胞瘤中的多核巨细胞。中华骨科杂志14(11):679-681 1994

6、郭卫, 冯传汉，等骨肉瘤标本中P53抗癌基因异常的研究。中华外科杂志32(7):412-415 1994

7、郭卫, 冯传汉，等。骨巨细胞瘤的细胞遗传学研究。中华外科杂志33(2):97-101 1995

8、郭卫, 黄承达。骨肉瘤组织中淋巴细胞及巨噬细胞浸润的观察。中华骨科杂志12(2):141-143 1992

9、郭卫黄承达。骨肿瘤患者外周血中T淋巴细胞亚群分布的研究。中华外科杂志28(4):235-237 1990

10、Guo Wei et al (1999) Mechanisms of Methotrexate Resistance in Osteosarcoma. Clin Cancer Res 5: 621.

11、Guo Wei et al (1999) Expression of Genes Encocding Bone Morphogenetic Proteins and Their Receptors in Sarcomas.  Clin Orthop 8：175-183.

12、Guo Wei, et al (1999) CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. Int. J Cancer 80, 199-204.

13、Guo Wei, et al (2000) Secondary Genetic Alterations in Ewing’sarcoma: Prognostic Impact of INK4A Deletion.  Cancer 89(4):793-799.

14、Guo Wei, et al (1999) COMPARATIVE FREQUENCY OF BONE SARCOMAS AMONG DIFFERENT RACIAL GROUPS. Chinese Medical Journal. (English Ed) 112(12):1101-1104.

15、Guo Wei, et al. Paclitaxel-induced apoptosis in osteosarcoma cell line U-2 OS.  Chinese Medical Journal. (English Ed) 115（12）1796-1801, 2002.

16、哈力南郭卫，冯传汉，等。nm23-H1基因与恶性及半恶性骨肿瘤相关性的初步报告。中华外科杂志36(8):477-479 1998

17、Guo Wei, et al. Dddeletion,mutation of p16 gene and CDK4 gene amplification in osteosarcoma 临床骨科杂志2(4):241-244 1999

18、郭卫。成骨细胞相关基因在软骨肉瘤中的表达。中华外科杂志39(1):56-59 2001

19、郭卫、冯传汉，等。骨与软组织肉瘤的细胞及分子生物学。中华骨科杂志20（增刊）：30-39，2001。

20、郭卫，等。恶性肿瘤的免疫治疗进展。中华骨科杂志20（增刊）：80-84，2000。

21、徐万鹏，郭卫，杨荣利。骨肿瘤的保肢术及其进展。中华骨科杂志20（增刊）：47-49，2000。

22、郭卫。骨与软组织肿瘤术后功能重建的评估标准。中华骨科杂志21（10）：635-636，2001。

23、郭卫, 等。骨的炎症性肌纤维母细胞瘤一例。中华外科杂志40（3）：240，2002。

24、燕太强，郭卫，等。畸型性骨炎。中华骨科杂志22（2）：100-102，2002。

25，燕太强，郭卫。原发性甲状旁腺机能亢进症引起的全身多发性骨吸收。中华骨科杂志22（7）：2002。

26、郭卫。骨肉瘤中cbfa1基因表达与临床因素的相关性研究。中华骨科杂志         20(1):16-20 2000.

27、郭卫。骨肉瘤成骨细胞表型与临床因素的相关性研究。中华骨科杂志22（7）：410-413，2002。

28，李茂廷，郭卫，等。尤文肉瘤与滑膜肉瘤的基因诊断。中国骨肿瘤骨病，1（2）：104-108，2002。

29，李茂廷，郭卫。骨与软组织肉瘤的特异性染色体易位。中华骨科杂志21（9）：566-569，2001。

30，曾春，郭卫等。紫衫醇诱导骨肉瘤细胞系凋亡的体外研究。中华骨科杂志22（11）：675-679，2002。

31，康立新，郭卫，等。紫衫醇对尤文肉瘤细胞系诱导凋亡及生长抑制的研究。中国骨肿瘤骨病，2（5）：305-308，2003。

32，郭卫、冯传汉。二磷酸盐治疗转移性骨肿瘤的作用机制。中华骨科杂志23（1）：36-38，2003。

33，郭卫，等。脊柱转移瘤的外科治疗。中华骨科杂志23（1）：19-22，2003。

34，郭卫，等。复合移植重建恶性骨肿瘤切除后骨缺损。中华骨科杂志23（4）：202-205，2003。

35，郭卫，等。骶尾部脊索瘤的手术治疗。北京大学学报（医学版），35（2）：159-162，2003。

36，燕太强，郭卫，等。骨单发性浆细胞瘤的诊治。中华外科杂志41（10）：749-752，2003。

37，郭卫，等。骶骨肿瘤的手术治疗。中华外科杂志41（11）827-831，2003。

38，李西成，郭卫。多发性骨髓瘤的外科治疗。中华外科杂志42（1）48-51，2004。

39，汤小东，郭卫，等。阿霉素海藻酸钠-壳聚糖微囊治疗兔VX2肢体肉瘤模型的实验研究。中华外科杂志41（12）940-943，2003。

40，郭卫，燕太强，等。恶性骨肿瘤的化疗进展。中华肿瘤杂志24（5）516-518，2002。

41, 郭卫，等。髋臼周围肿瘤的切除与重建。中华外科杂志42（23）1419-1422，2004

42，郭卫，等。成骨肉瘤的新辅助化疗的疗效分析。中华医学杂志, 84(14)1186-1190, 2004。

43，郭卫，等。全肘关节成型术重建肘部肿瘤切除后骨缺损。中华骨科杂志24（11）663-665 2004。

44，郭卫，汤小东，等。巨大锁骨软骨肉瘤切除后自体肩胛骨移植修复胸壁缺损一例报告。中华骨科杂志23（9）535，2003

45, 李南，郭卫，等。尤文肉瘤患者外周血中肿瘤细胞的检测及其意义。中国骨肿瘤骨病，3（1）44-50，2004。

46，杨毅，郭卫，等。干躁综合征导致多发性骨破坏及病理性骨折一例报告。中华骨科杂志24（11）700-701 2004。

47，李建，郭卫，等。骨肉瘤SAP值的测定及其临床意义。中国骨肿瘤骨病2（4）200-205 2004。

48, 曲华毅，郭卫，等。介导尤文肉瘤融合基因的重组腺病毒的构建及其在外周血中单个核细胞中的表达。中国骨肿瘤骨病3（3）161-166，2004。

49, 郭义，郭卫，等。尤文肉瘤基因免疫治疗的研究。中华实验外科杂志21（7）848-851 2004

50，汤小东，郭卫，等。大剂量顺铂股动脉灌注联合血液透析动物模型的实验研究。中国骨肿瘤骨病，2（4）217-230，2003

51, 汤小东，郭卫，等。手术联合椎体成形术治疗多发性脊柱肿瘤。中华外科杂志42（24），2004

52，李建，郭卫，等。影响骨肉瘤预后因素的探讨。中国骨肿瘤骨病3（6）374-379 2004。

53, 郭卫，等。肱骨近端肿瘤切除术后应用锁骨重建近端肱骨。中华骨科杂志25 (2) 107-109 2005。

54，唐顺，郭卫，等。树突状细胞与尤文肉瘤细胞融合诱导抗肿瘤免疫应答的体

外研究。中华外科杂志43（12）803-806，2005

55，郭卫，等。骨盆原发恶性骨肿瘤的手术治疗。中华骨科杂志25 (5) 276-279 2005。

56，郭卫，等。脊柱转移瘤的前路手术治疗。中国医学科学院学报27（2）179-184 2005。

57, 汤小东，郭卫，等。三氧化二砷诱导尤文肉瘤细胞凋亡及对EWS-Fli 1融合蛋白的影响。中国肿瘤临床32（22）1280-1283，2005。

58，杨荣利、徐万鹏、郭卫。特制半关节假体置换在儿童膝关节肿瘤中的应用。中国骨肿瘤骨病4（1）1-4 2005。

59，杨荣利、徐万鹏、郭卫。61例肢体转移癌的外科治疗。中国骨肿瘤骨病3（6）330-334 2004。

60，郭卫，等。髂骨翼肿瘤的切除与重建。中华外科杂志44（12）813-816，2006。

61，沈丹华，郭卫，杨毅，等。骨转移癌临床及病理学研究。中华病理学杂志35（6）324-327，2006。

62，郭卫，等。三氧化二砷联合化疗治疗III 期成骨肉瘤及尤文肉瘤的初步报告。中华外科杂志44（12）805-808，2006。

63，郎林，郭卫。人工关节置换治疗弥漫性腱鞘巨细胞瘤。中国骨肿瘤骨病5（2）83-86，2006。     

64，杨子明，郭卫，等。骨巨细胞瘤生物学特性及治疗对策高级学术论坛学术讨论纪要。中华外科杂志44（12）793-796，2006。

65, 郭卫，姬涛, 杨毅。肿瘤型人工关节重建下肢骨肉瘤切除后骨缺损。中国修复重建杂志20（10）970-974，2006

66，汤小东，郭卫，杨荣利，等。大段同种异体骨段移植重建四肢肿瘤切除后骨缺损。中国修复重建杂志20（10）985-988，2006

67，李南，郭卫，杨荣利，等。上肢骨肿瘤切除后骨缺损的自体骨移植重建。中国修复重建杂志，20（10）992-995，2006

68，郭卫，唐顺，杨毅，等。脊柱原发肿瘤的手术治疗策略。中华骨科杂志26 (12)793-797，2006。

69，郭卫，等。脊柱转移瘤的外科治疗效果。中国脊柱脊髓杂志16（12）905-908，2006。

70，郭卫，冯传汉。骨与软组织肿瘤的细胞及分子遗传学研究进展。国外医学遗传学分册，1993，1：15-17。

71，汤小东，郭卫，等。普通软骨肉瘤复发后病理进级和去分化改变。中华骨科杂志27 (2)101-105，2007

72，郭卫，杨毅，李晓，等。四肢骨巨细胞瘤的外科治疗。中华骨科杂志27 (3) 177-182，2007。

73，郭卫，王显海，李大森，等。肿瘤型人工膝关节置换治疗骨肉瘤疗效及并发症分析。中华外科杂志2007，45（12）825-828。

74，Guo Wei, Dasen Li, Xiaodong Tang, et al. Modular Hemipelvic Prosthesis Reconstruction of Acetabulem after Resection of Periacetabular Tumors. Clin Orthop, 461:180-188, 2007.

75，郭卫，汤小东，杨毅，等。骶骨肿瘤的分区及手术方法探讨。中国脊柱脊髓杂志17（8）605-610，2007。

76，郭卫。原发性恶性骨肿瘤的治疗原则及若干问题。中华外科杂志45（10）649-651，2007。

77，郭卫，杨毅，李晓，等。股骨近端肿瘤切除后人工假体重建。中华外科杂志45（10），2007。

78，汤小东，郭卫，杨毅，等。儿童膝关节恶性骨肿瘤的保肢治疗。中华外科杂志45（10），2007。

79，李晓，郭卫，杨荣利，等。脊柱原发软骨肉瘤的外科治疗。中国脊柱脊髓杂志17（7）507-511，2007。

80，赵会，唐顺，曲华毅，郭卫，等。四种不同尤文肉瘤树突状细胞免疫疫苗的体内外抗肿瘤免疫应答研究。北京大学学报（医学版），39（4）403-408，2007。

81，李晓，郭卫，沈丹华，等。骨肉瘤细胞和外周血淋巴细胞ERCC2 与ERCC4基因表达及其临床意义。北京大学学报（医学版），39（5）467-471，2007。

82，燕太强，郭卫，杨荣利，沈丹华。关节置换术后继发恶性肿瘤。中国骨肿瘤骨病杂志，2007，6(3)：136-138。

83，燕太强，杨荣利，郭卫，沈丹华。胫骨骨的血管平滑肌肉瘤伴全身多发转移1例报道并文献综述。北京大学学报（医学版），2007，39(4)：369-373。

84，王国文，郭卫，汤小东，等。基因芯片筛选软骨肉瘤去分化相关基因初步探讨。中国肿瘤临床，2007，34（20）1146-1149。

85，姬涛，郭卫，等。骨肿瘤病理活检有效性的影响因素分析。中国矫形外科杂志2007;15(17):1296。

86，曲华毅，郭卫，唐顺，等。25例骨嗜酸性肉芽肿的诊断和治疗。中国肿瘤临床，2007，34（3）157-167。

87，沈丹华，杨毅，郭卫，等。儿童骨原发性非霍奇金淋巴瘤3例临床病理分析及文献复习。诊断病理学杂志，2004，11（5）323-325。

88，郭卫，汤小东，李晓，等。骨盆和骶骨的骨巨细胞瘤。中华外科杂志，46（7）501-505，2008。

89，郭卫。恶性骨肿瘤保肢治疗的原则及问题。中华关节外科杂志，2007，1（5）257-260。

90，郭卫汤小东杨毅，等。骨盆转移瘤外科治疗的疗效评估。中华外科杂志，46（12）891-894，2008

91，姬涛，郭卫，杨荣利，等。下肢恶性骨肿瘤保肢术后假体生存分析及功能评估。中华骨科杂志，2008，28（2）117-121。

92，柳剑，郭卫、杨荣利，等。72例骨肉瘤患者化疗效果评估——临床、放射及病理学对照研究。中华外科杂志，2008，46（15）1166-1170。

93，柳剑，郭卫、杨荣利，等。骨肉瘤术前化疗效果的MRI评估。中国骨肿瘤骨病杂志，2008，7(3)：133-137。

94，郭卫曲华毅杨荣利，等。骶骨转移瘤的外科治疗评价。中国脊柱脊髓杂志，2008，18（6）415-419。

95，郭卫杨毅姬涛。肩胛带骨肿瘤的外科治疗结果及评价。中华骨科杂志，2008，28（10）807-812。

96，郭卫，唐顺，杨荣利，等。定制型人工肘关节重建肘部肿瘤切除后骨缺损。中华外科杂志，46（18），2008。

97, Guo W, Guo Y, Tang S, et al. Dendritic Cell-Ewing’s Sarcoma Cell Hybrids Enhance Antitumor Immunity. Clin Orthop Relat Res.466:2176-2183, 2008

98, Guo W , Ji T, Tang X, et al. Megaprostheses Replacement for Primary Tumors around the Knee-Experience from Peking University. J Bone Joint Surg [Br], 2008, 90-B:1084-1089.

99，Ji T, Guo W, Shen DH, et al. Intradural spinal seeding and fatal progression of a sacrococcygeal chordoma: a case report. Chin Med J 2008, 1210:1-4

100，郭卫，杨毅，杨荣利。骶骨区神经源性肿瘤的手术治疗策略。中国脊柱脊髓杂志，18（10）761-765，2008

101，Peng C, Guo W, Yang Y, et al. Downregulation of SS18-SSX1 expression by small interfering RNA inhibits growth ang induces apoptosis in human synovial sarcoma cell line HS-SY-a in vitro. Euro J Cancer Preven, 2008, 17：392-398.

102，郭卫。骨盆恶性肿瘤的外科治疗原则。中华外科杂志，46（12）881-883，2008。

103，汤小东，郭卫。骨盆原发恶性肿瘤的切除与重建。中华外科杂志，46（12）904-907，2008。

104，郭卫，杨毅，汤小东，等。骨盆环软骨肉瘤的手术治疗。中华骨科杂志，2008，28（2）96-100

105，姬涛，郭卫。肿瘤型人工关节的发展。中华关节外科杂志，2008，2（3）57-60。

106，郭卫，姬涛，杨毅。肱骨骨肉瘤的治疗结果评价。中国骨与关节外科，1（3）179-184，2008。

107，曲华毅，郭卫，杨荣利，等。骨原发恶性纤维组织细胞瘤的治疗。中华外科杂志，2008，46（21）1669-1670。

108，唐顺，郭卫，杨荣利。127例肺癌骨转移患者随访的预后因素分析。中国肿瘤临床，2008，35（23）1335-1338。

109，杨荣利，曲华毅，燕太强，等。肩胛下经胸入路切除及重建胸椎肿瘤。中华外科杂志，46（19）1486-1489。

110，杨荣利，郭卫，燕太强，等。开放性椎体成型术治疗脊椎转移癌和多发性骨髓瘤。中华骨科杂志，2008，28（12）1028-1032。

111，燕太强，杨荣利，郭卫。腓骨近端成骨肉瘤的外科治疗，中华外科杂志，2008，46（9）661-663。

112，刘巍峰，郭卫，等。移植性人骨肉瘤OS-732裸鼠模型的建立。中国骨肿瘤骨病，2008，7（4）204。

113，柳健，郭卫，等。影像学在评估骨肉瘤化疗中的价值。中国矫形外科，2008，16（17）1329。

114，汤小东，郭卫，杨荣利，等。未知来源骨转移癌病人的诊断。中国矫形外科，2008，17（1）7-10。

115，唐顺，董森，郭卫，等。腹主动脉球囊阻断控制骶骨肿瘤切除术中出血的效果。中国脊柱脊髓杂志，19（2）85-89，2009

116，郭卫杨荣利姬涛。累及骶骨的骨盆恶性肿瘤切除及重建。中华外科杂志，47（10）766-769，2009。

117，姬涛，郭卫。骨盆环三维有限元模型的建立。中国组织工程与临床康复，2009;13（9），1625-1628。

118，燕太强，等。骨血管源性恶性肿瘤的临床分析。中华骨科杂志，2009，29（8）723-727。

119,  姬涛，郭卫。有限元方法分析不同截骨平面对组配式半骨盆假体固定效果的影响。中国组织工程与临床康复，2009；13

120，Hui Zhao, Wei Guo, Changliang Peng, et al. Arsenic trioxide inhibits the growth of Adriamycin resistant osteosarcoma cells through inducing apoptosis. Mol Biol Rep,2010, 37(5):2509-2515.

121，姬涛，郭卫，董森，等。组配式人工半骨盆假体重建的生物力学分析。中华骨科杂志，2009，29（10）954-959。

122，王国文，郭卫，汤小东，等。顺铂纳米脂质体对骨肉瘤Saos-2细胞的杀伤作用及在荷瘤小鼠中的组织分布。北京大学学报（医学版），41（5）525-530，2009。

123，Tang X, Guo W, Yang R, et al. Assessment of Risk Factors for Blood Loss during Sacral Tumor Resection. Clin Orthop Relat Res. 2009, Jun;467(6):1599-604.

124，Guo W. Tang X, Yang Y, et al. Outcome of conservative surgery for giant cell tumor of the sacrum.Spine. 2009, May 1;34(10):1025-31.

125，Tang X, Guo W, Yang R, et al. Evaluation of blood loss during limb salvage surgery for pelvic tumours. Int Orthop. 2009 Jun;33(3):751-6.

126，郭卫燕太强汤小东，等。髋臼及其周围肿瘤的分区与重建方法。中华骨科杂志，29（2）134-139，2009。

127，Guo Wei, Tang Xiaodong , Yang Yi, et al.  Strategy of Surgical Treatment of Sacral Neurogenic Tumors. Spine, 2009, 34(23):2587-2592.

128，郭卫，燕太强，汤小东，等。骶骨脊索瘤的手术治疗结果评价。中华外科杂志，47（16）1224-1227，2009。

129，Tang X, Guo W, Yang R, et al. Custom-made prosthesis replacement for reconstruction of elbow after tumor resection.J Shoulder Elbow Surg (2009) 18,796-803.

130，郭卫，李大森，杨毅，等。脊柱骨巨细胞瘤的手术治疗策略。中国脊柱脊髓杂志，2009，19（12）899-903。

131，Chang-liang Peng, Wei Guo, Tao Ji, et al. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway. Cancer Biology & Therapy. 8:18, 1729-1736. 2009.

132，姬涛，郭卫，董森，等。组配式人工半骨盆假体在步行周期载荷下的有限元分析。北京大学学报（医学版），41（6）13-18，2009。

133，孙馨，郭卫，杨荣利，等。15例腺泡状软组织肉瘤的临床特点及预后分析。中国癌症杂志，2009，19（10）784-787。

134，汤小东，郭卫，杨荣利，等。肱骨近端骨肉瘤的保肢治疗。中国矫形外科，2009，17（23）1763-1766。

135，郭卫。骨转移瘤外科治疗专家共识。中华骨科杂志，2009，29（12）1177-1184。

136，郭卫，柳建，孙馨。四肢IIB成骨肉瘤的化疗效果评价。中华外科杂志，47（21）1634-1637，2009。

137，郭卫，孙馨，姬涛，等。髋臼转移瘤的外科治疗。中华外科杂志，47（22）1718-1721，2009。

138，杨荣利，郭卫，汤小东，等。后路I 期整块全脊椎切除治疗胸椎及腰椎肿瘤初步经验。中华外科杂志，47（24）1908-1910，2009。

139，孙馨，郭卫，杨荣利，等。骶骨肿瘤术后的神经功能损伤的评估。中国肿瘤临床与康复，2010，17（2）111-114。

140，孙馨，郭卫，杨荣利，等。99例骨肉瘤肺转移患者随访结果分析。中华骨科杂志，2010，30（7）666-673。

141，海国栋，郭卫，姬涛，等。股骨近端骨纤维结构不良的外科治疗—一种分区方法。中国矫形外科，18（1）26-29，2010。

142，杨荣利，郭卫，汤小东，等。后路I 期整块全脊椎切除治疗胸腰椎肿瘤。中国脊柱脊髓杂志，2010，20（1）34-38。

143，汤小东，郭卫，杨荣利，等。膝关节定制型肿瘤假体的翻修。中国修复重建外科杂志，24（1）5-10，2010。

144，任婷婷，郭卫，卢新昌，等。三氧化二砷抑制骨肉瘤转移和侵袭的体外研究。肿瘤研究与临床，2009，21（12）796-798。

145，曲华毅，郭卫，杨荣利。骶骨肿瘤伤口相关并发症的危险因素分析与对策。中国矫形外科，18（3）212-215，2010。

146，李大森，郭卫，杨荣利，等。脊椎血管瘤的外科治疗策略。中国矫形外科，18（5）385-388，2010。

147, 李大森，郭卫，曲华义，等。单纯广泛切除治疗低度恶性中心型成骨肉瘤。中国矫形外科，18（6）452-456，2010。

148，郭卫，李大森，唐顺，等。骶骨肿瘤的类型和临床特点。中国脊柱脊髓杂志，2010，20（5）380-384。

149，郭卫。I型神经纤维瘤病性脊柱侧凸合并椎旁肿瘤的诊治。中国脊柱脊髓杂志，2010，20（5）361-362。

150, 郭卫，汤小东，李大森，等。全骶骨切除术治疗骶骨多节段恶性肿瘤。中国脊柱脊髓杂志，2010，20（6）472-476。

151, Tang X, Guo W, Yang R, et al.  Aortic balloon occlusion decrease blood loss during sacral tumor resection.  J Bone Joint Surg Am, 2010, 92(8):1747-53.

152，Wei Guo, Dasen Li, Xiaodong Tang, et al. Surgical Treatment of Pelvic Chondrosarcoma Involving Periacetabulum. J Surg Oncol, 2010, 101(2):160-165.

153, 臧杰，郭卫，杨荣利，等。骨原发尤文肉瘤预后相关因素的分析。中华外科杂志，48（12）896-899。

154, 郭卫，孙馨，姬涛。骨盆骨肉瘤的外科治疗策略探讨。中华外科杂志，48（13）994-998。

155，郭卫唐顺燕太强，等。切刮术治疗骶骨骨巨细胞瘤的结果评价。中国脊柱脊髓杂志，2010，20（8）635-639

156，姬涛，郭卫，唐顺，等。组配式人工半骨盆假体重建后耻骨板断裂的非线性有限元分析。中国组织工程与临床康复，2010；14（35）6500-6503

157，姬涛，郭卫，杨荣利，等。GMRS组配式人工关节重建骨肿瘤切除后骨缺损的近期疗效。中国修复重建杂志，24（10）1192-1195，2010。

158，董森，姬涛，郭卫，等。不同收敛条件对骨盆三维有限元模型计算结果的影响。中国组织工程与临床康复，2010；14（4）581-584。

159，姬涛，郭卫，等。组配式人工半骨盆假体在步行周期载荷下的有限元分析。北京大学学报医学版，2010；42（2）：192。

160，卢新昌，汤小东，郭卫，等。Runx2在去分化软骨肉瘤细胞系中的表达及意义。肿瘤研究与临床；2010；22（4）:231。

161，燕太强，郭卫等。髌骨骨巨细胞瘤的外科治疗。中国骨肿瘤骨病，2010，9（1）60-63。

162，燕太强，郭卫等。下肢远端原发恶性骨肿瘤患者的生存和肢体功能分析。中华外科杂志，2010，48（20）:1550-1555。

163，李广学，郭卫，等。骨样骨瘤的诊断与治疗。中国骨伤；2010；23（8）:629-631。

164，Du Zhi-Ye, Zang Jie, Guo Wei, et al. Expert’s agreement on therapy for bone metastases. Orthopaedic Surgery; 2010; 2(4)：241-253.

165, Tang G, Yan T, Guo W, et al. "(-)-Epigallocatechin-3-gallate induces apoptosis and suppresses proliferation by inhibiting the human Indian Hedgehog pathway in human chondrosarcoma cells. J Cancer Res Clin Oncol. 2010，136：1179-1185.

166, 郭卫。脊柱原发性恶性肿瘤的外科治疗策略。中国脊柱脊髓杂志，2010，20（8）622-623。

167, Lu X, Tang X, Guo W, et al. Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking RAF/ERK/MEK pathway. J Surg Oncol, 2010, 102(7):821-826.

168，Tang X, Lu X, Guo W, Ren T, et al. Different expression of Sox9 and Runx2 between chondrosarcoma and dedifferentiated chondrosarcoma cell lines. Eur J Cancer Prev. 2010 ;19(6):466-471..

169，姬涛，郭卫。第十五届国际保肢大会（ISOLS）会议纪要。中华骨科杂志；2010 ;30(8) :812-815。

170，Ren Ting-ting, Guo Wei, et al. Arsenic trioxide inhibits osteosarcoma cell innasiveness via MAPK signaling pathway. Cancer Biol Ther. 2010;10(3);251-257.

171，Ji Tao, Guo Wei, et al. Reconstruction of type II+III pelvic resection with a modular hemipelvic endoprosthesis : a finite elememt analysis study.  Orthopaedic Surgery; 2010;2(4):272-277.

172，燕太强，董森，张学民，等。血管重建在骨与软组织肉瘤保肢术中的应用。

中华骨科杂志，2011，31（2）113-118。

173，燕太强，郭卫。脊椎转移瘤的微创外科治疗进展。中国脊柱脊髓杂志，2011，21（3）244。

174，燕太强，郭卫，杨荣利，等。单纯后路经椎弓根椎体次全切除内固定联合人工椎体置换治疗胸腰椎转移瘤。中国骨肿瘤骨病，2011, 10（1）6-10。

175，李广学，郭卫。脊柱副神经节瘤的诊断和治疗。中国脊柱脊髓杂志，2011，21（3）258-260。

176，郭卫，孙馨，燕太强，等。保留上肢的肩胛带切除术治疗肩胛带恶性肿瘤。

中华骨科杂志，2011，31（6）587-593。

177，李广学，郭卫。脊柱骨母细胞瘤的诊断和治疗。中国骨肿瘤骨病，2011,10（2）127-131。

178，T. Ji, W. Guo, R.-L.Yang, et al. Clinical outcome and quality of life after surgery for peri-acetabular metastases. J Bone Joint Surg[Br],2011;93-B：1104-10.

179，T Yan, G Tang, T Ren，et al. RNAi-mediated COPS3 gene silencing inhibits metastasis of osteogenic sarcoma cells. Cancer Gene Therapy (2011) 18, 450–456.

180, D. Li, W. Guo, X. Tang, et al. Surgical classification of different types of en bloc resection for primary malignant sacral tumors. Eur Spine J（2011）20：2275-2281.

181，X．Tang，W. Guo, R. Yang, et al. Reconstruction with constrained prosthesis after total scapulectomy. J Shoulder Elbow Surg (2011)20, 1163-1169.

182，杨毅，杨荣利，郭卫。59例肱骨转移癌手术治疗的回顾性分析。北京大学学报（医学版）43（5）681-685，2011。

183，王毅飞，郭卫，姬涛，等。肿瘤型旋转铰链式人工膝关节置换术后脱位的原因分析与治疗。中国骨与关节杂志，2012，1（2）146-150。

184，Tang X, Guo W, Ji T. Reconstruction with modular hemipelvic prosthesis for the resection of solitary periacetabular metastasis. Arch Orthop Trauma Surg （2011）131：1609-1615。

185, F.Zhao, W.Guo, et al. Expression of stromal derived factor-1(SDF-1)and chemokine receptor(CXCR4)in bone metastasis of renal carcinoma. Mol Biol Rep, 2011, 38(2):1039-1045.

186，李广学，郭卫。软组织恶性纤维组织细胞瘤的治疗策略和预后分析。中华外科杂志2011 49（11）974-977。

187，李广学，郭卫，杨荣利等。骨恶性纤维组织细胞瘤预后因素分析。中华外科杂志2011 49（8）733-736。

188，杜志业，郭卫，杨荣利，等。滑膜肉瘤预后相关因素分析。中华外科杂志2011 49（11）991-994。

189, 李大森，郭卫，杨荣利，等。带翼型髋臼加强杯在重建髋臼肿瘤切除后骨缺损中的应用。中国修复重建外科杂志，2011，25（12）1409-1413。

190, W. Guo, X. Sun, J. Zang & H. Qu. Intralesional Excision versus Wide Resection for Giant Cell Tumor Involving the Acetabulum: Which is Better?

Clin Orthop Relat Res. 2012, 470 :1213-1220.

191，S．Zhang, W. Guo, T.T.Ren, et al. Arsenic trioxide inhibits Ewing’s sarcoma cell invasiveness by targeting p38MAPK and c-Jun N-terminal kinase. Anti Cancer Drugs. 2012, 23(1)108-118.

192，燕太强，郭卫，杨荣利等。骨水泥椎体成形在治疗脊柱转移瘤中的临床应用。中国脊柱脊髓杂志，2012，22（4）318-323。

193，Guo W, Sun X, Ji T, Tang X. Outcome of surgical treatment of pelvic osteosarcoma.J Surg Oncol. 2012；106:406-410

194，Xie L, Guo W, Li Y, et al. Pathologic Frecture Dose Not Influence Local Recurrence and Survival in High-Grade Extremity Osteosarcoma With Adequate Surgical Margians. J Surg Oncol. 2012;106:820-825.

195，齐典文，郭卫，杨荣利等。18F-FDG PET/CT诊断骨与软组织肉瘤术后复发及转移。中国骨与关节杂志，2012，1（3）239-245。

196，尉然，郭卫。脊柱转移癌外科治疗现状及进展。中国脊柱脊髓杂志，2012，22（8）743-748.

197，杜志业，郭卫，杨荣利等。骨的孤立性转移瘤的预后相关因素分析。中国矫形外科，2012，20（16）1470-1473。

198，孙馨，郭卫，杨荣利，等,15例腺泡状软组织肉瘤的临床特点及预后分析。中国癌症杂志，2012，22（9）658-662.

199, 郭卫。恶性骨肿瘤保肢治疗中存在的问题。中华骨科杂志，2012,32（11）995.

200，尉然，郭卫，杨毅。甲状腺癌骨转移的外科治疗及预后因素分析。中华骨科杂志，2012,32（11）1073-1080.